Neuro-oncology, 2021. Brief analysis of the new World Health Organization classification of tumors of the central nervous system

Authors

  • Marina Matsko St Petersburg Clinical Scientific-Practical Center of Oncology, 68A, ul. Leningradskaya, Pesochny, St Petersburg, 197758, Russian Federation ; St Petersburg State University, 7–9, Universitetskaya nab., St Petersburg, 199034, Russian Federation ; St Petersburg Medical Social Institute, 72A, Kondratievsky pr., St Petersburg, 195271, Russian Federation
  • Evgeny Matsko St. Petersburg State University, 7–9, Universitetskaya nab., St. Petersburg, 199034, Russian Federation ; St. Petersburg Research Institute of Phthisiopulmonology, Health Ministry of Russia, 2–4, Ligovskiy pr., St. Petersburg, 191036, Russian Federation

DOI:

https://doi.org/10.21638/spbu11.2022.202

Abstract

The author’s translation of the new World Health Organization classification (2021) of tumors of the central nervous system is presented. Its fundamental differences from the previous edi100 tion are considered with a list of the main new nosological units. It is important to note that central nervous system tumors were divided into “adult-type diffuse gliomas” and “paediatric-type diffuse gliomas” (low-grade and high-grade). A new section has appeared — “gliomas, glioneuronal tumors, and neuronal tumors”. This rubric includes “ependymal tumors” and “glioneuronal and neuronal tumors”. In the fifth-edition Central Nervous System Tumours volume of the Classification, the sections have disappeared: “other astrocytic tumors” and “other gliomas”. Many nosologies from these sections, according to growth patterns, have formed a new rubric — “сircumscribed astrocytic gliomas. The approach to the classification of ependymomas has been fundamentally changed. Now it is based on anatomical localization and its corresponding genetic aberration. Attention is paid to the growing role of molecular diagnostics, which is fundamental in terms of nosology, and to the difficulties associated with the transition to the new version of classification. Information about the degree of malignancy of the most common neoplasms of this localization is given.

Keywords:

WHO classification, tumors of the central nervous system, the degree of malignancy of the CNS tumors, molecular genetics, neuro-oncology

Downloads

Download data is not yet available.
 

References


References

Louis D. N., Ohgaki H., Wiestler O. D., Cavenee W. K. WHO Classification of Tumours of the Central Nervous System. 4th ed., rev. Lyon, IARC, 2016, 408 p.

WHO Classification of Tumours Editorial Board. Central nervous system tumours. Lyon (France): International Agency for Research on Cancer. WHO Classification of Tumours Series, 5th ed., 2021, vol. 6.

Matsko M. V., Matsko D. E., Imyanitov E. N., Ievleva A. G. IDH1/2 (isocitrate dehydrogenase) is an important prognostic marker in neuro-oncology. Rossiiskii neirokhirurgicheskii zhurnal, 2013, vol. V, p. 200. (In Russian)

Dang L., White D. W., Gross S., Bennett B. D., Bittinger M. A., Driggers E. M., Fantin V. R., Jang H. G., Jin S., Keenan M. C., Marks K. M., Prins R. M., Ward P. S., Yen K. E., Liau L. M., Rabinowitz J. D., Cantley L. C., Thompson C. B., Vander Heiden M. G., Su S. M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 2009, vol. 462, no. 727, pp. 739–744. https://doi.org/10.1038/nature08617

Parsons D. W., Jones S., Zhang X., Lin J. C., Leary R. J., Angenendt P., Mankoo P., Carter H., Siu I. M., Gallia G. L., Olivi A., McLendon R., Rasheed B. A., Keir S., Nikolskaya T., Nikolsky Y., Busam D. A., Tekleab H., Diaz L. A. Jr., Hartigan J., Smith D. R., Strausberg R. L., Marie S. K., Shinjo S. M., Yan H., Riggins G. J., Bigner D. D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V. E., Kinzler K. W. An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science, 2008, vol. 321, no. 5897, pp. 1807–1812. https://doi.org/10.1126/science.1164382

Dang L., Yen K., Attar E. C. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol., 2016, vol. 27, no. 4, pp. 599–608. https://doi.org/10.1093/annonc/mdw013

Mondesir J., Willekens C., Touat M., de Botton S. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J. Blood Med.,2016, vol. 7, pp. 171–180. https://doi.org/10.2147/JBM. S70716

Louis D. N., Perry A., Wesseling P., Brat D. J., Cree I. A., Figarella-Branger D., Hawkins C., Ng H. K., Pfister S. M., Reifenberger G., Soffietti R., von Deimling A., Ellison D. W. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol., 2021, vol. 23, no. 8, pp. 1231–1251. https://doi.org/10.1093/neuonc/noab106

Downloads

Published

2022-10-31

How to Cite

Matsko, M. ., & Matsko, E. . (2022). Neuro-oncology, 2021. Brief analysis of the new World Health Organization classification of tumors of the central nervous system. Vestnik of Saint Petersburg University. Medicine, 17(2), 88–100. https://doi.org/10.21638/spbu11.2022.202

Issue

Vol. 17 No. 2 (2022)

Section

Neurology. Neurosurgery. Psychiatry

License

Articles of "Vestnik of Saint Petersburg University. Medicine" are open access distributed under the terms of the License Agreement with Saint Petersburg State University, which permits to the authors unrestricted distribution and self-archiving free of charge.